Bkemv is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria and for those with atypical hemolytic uremic syndrome, according to a May 28 news release from the FDA.
Bkemv is the 53rd approved biosimilar in the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
